JP2022501016A - 脳障害、特に、認知障害の診断および治療のための長鎖ノンコーディングＲＮＡ（ｌｎｃＲＮＡ） - Google Patents

脳障害、特に、認知障害の診断および治療のための長鎖ノンコーディングＲＮＡ（ｌｎｃＲＮＡ） Download PDF

Info

Publication number
JP2022501016A
JP2022501016A JP2021512725A JP2021512725A JP2022501016A JP 2022501016 A JP2022501016 A JP 2022501016A JP 2021512725 A JP2021512725 A JP 2021512725A JP 2021512725 A JP2021512725 A JP 2021512725A JP 2022501016 A JP2022501016 A JP 2022501016A
Authority
JP
Japan
Prior art keywords
lnc
lncrna
tcons
lncrnas
dementia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021512725A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022501016A5 (https=
Inventor
サリハ・ムサウイ
フセイン・フィラ
エリック・ショルダン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amoneta Diagnostics SAS
Original Assignee
Amoneta Diagnostics SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amoneta Diagnostics SAS filed Critical Amoneta Diagnostics SAS
Publication of JP2022501016A publication Critical patent/JP2022501016A/ja
Publication of JP2022501016A5 publication Critical patent/JP2022501016A5/ja
Priority to JP2024021135A priority Critical patent/JP2024073440A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021512725A 2018-09-05 2019-09-05 脳障害、特に、認知障害の診断および治療のための長鎖ノンコーディングＲＮＡ（ｌｎｃＲＮＡ） Pending JP2022501016A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024021135A JP2024073440A (ja) 2018-09-05 2024-02-15 脳障害、特に、認知障害の診断および治療のための長鎖ノンコーディングＲＮＡ（ｌｎｃＲＮＡ）

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862727210P 2018-09-05 2018-09-05
US62/727,210 2018-09-05
PCT/EP2019/073775 WO2020049135A1 (en) 2018-09-05 2019-09-05 Long non-coding rnas (lncrnas) for the diagnosis and therapeutics of brain disorders, in particular cognitive disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024021135A Division JP2024073440A (ja) 2018-09-05 2024-02-15 脳障害、特に、認知障害の診断および治療のための長鎖ノンコーディングＲＮＡ（ｌｎｃＲＮＡ）

Publications (2)

Publication Number Publication Date
JP2022501016A true JP2022501016A (ja) 2022-01-06
JP2022501016A5 JP2022501016A5 (https=) 2022-09-12

Family

ID=67902523

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021512725A Pending JP2022501016A (ja) 2018-09-05 2019-09-05 脳障害、特に、認知障害の診断および治療のための長鎖ノンコーディングＲＮＡ（ｌｎｃＲＮＡ）
JP2024021135A Pending JP2024073440A (ja) 2018-09-05 2024-02-15 脳障害、特に、認知障害の診断および治療のための長鎖ノンコーディングＲＮＡ（ｌｎｃＲＮＡ）

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024021135A Pending JP2024073440A (ja) 2018-09-05 2024-02-15 脳障害、特に、認知障害の診断および治療のための長鎖ノンコーディングＲＮＡ（ｌｎｃＲＮＡ）

Country Status (5)

Country Link
US (1) US12344895B2 (https=)
EP (1) EP3847279B1 (https=)
JP (2) JP2022501016A (https=)
CN (1) CN113286895A (https=)
WO (1) WO2020049135A1 (https=)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240056729A (ko) * 2016-05-18 2024-04-30 보이저 테라퓨틱스, 인크. 조절성 폴리뉴클레오티드
EP3679157B1 (en) 2017-09-05 2024-12-18 Amoneta Diagnostics Non-coding rnas (ncrna) for the diagnosis of cognitive disorders
CN110564833A (zh) * 2019-08-23 2019-12-13 杭州迪安医学检验中心有限公司 一种用于ffpe样本dna质控的试剂盒及检测方法
AU2020447192A1 (en) * 2020-05-11 2023-01-19 Samsung Bioepis Co., Ltd. Human genome-derived polynucleotide and method for producing polypeptide of interest using same
CN111518906B (zh) * 2020-05-12 2022-07-05 广州医科大学附属第五医院 肝细胞癌的复发预测及治疗中lncRNA01622的应用
CN113667737A (zh) * 2020-07-31 2021-11-19 上海市精神卫生中心（上海市心理咨询培训中心） Mci诊断标志物、mci诊断试剂盒及相应的检测方法
CN114832108B (zh) * 2020-10-13 2024-03-22 澜杉(北京)生物科技有限公司 一种阿尔茨海默病的治疗药物
CN112575076A (zh) * 2020-11-02 2021-03-30 深圳恒生医院 一种用于检测和评估早期自然流产的LncRNA标记物及应用其的产品
CN112795655B (zh) * 2021-02-08 2021-08-24 青岛市中心医院 一种结直肠癌诊断标志物及其诊断试剂盒
CN113262304B (zh) * 2021-04-26 2022-12-06 暨南大学 miR-4435-2HG和/或GDAP1基因抑制剂在制备治疗AML药物中的应用
CN113862366A (zh) * 2021-10-26 2021-12-31 山东师范大学 一种肝癌诊断的生物标志物及其诊断试剂盒
CN113981091B (zh) * 2021-11-24 2025-02-28 中南大学湘雅医院 Wtap作为鼻咽癌预后预测标志物及检测引物与试剂盒
CN114236123B (zh) * 2021-12-13 2024-04-19 深圳华大基因股份有限公司 标志物在预测妊娠期糖尿病风险中的应用
CN114214290B (zh) * 2021-12-27 2023-12-01 吉林大学 一种重组腺病毒ADV-lncRNA Gm44275及其构建方法和应用
CN114480390B (zh) * 2022-01-26 2023-10-20 广州市红十字会医院（暨南大学医学院附属广州红十字会医院） 靶向抑制ZNF22基因表达的siRNA、siRNA质粒、慢病毒及其构建方法和应用
WO2023206347A1 (zh) * 2022-04-29 2023-11-02 苏州瀛创生物科技有限公司 作为早老性痴呆诊断标志物的ddit4l剪切产物
US11866707B2 (en) 2022-05-18 2024-01-09 Zhejiang Cancer Hospital Use of non-coding RNA SNHG17 as biomarker and therapeutic target
CN114717242A (zh) * 2022-05-20 2022-07-08 中国医学科学院肿瘤医院 Loc107984813在诊断、预测预后、治疗癌症中的应用
CN117138043A (zh) * 2022-05-24 2023-12-01 北京大学 Myc增强子基因编辑系统及其在制备治疗雌激素受体阳性乳腺癌产品中的应用
CN114886910B (zh) * 2022-06-21 2023-09-22 上海市同仁医院 Linc00938在神经细胞凋亡中的应用
CN115089715B (zh) * 2022-07-06 2023-06-30 四川大学 Alpk1基因作为中枢神经系统疾病预防或治疗靶点的应用
CN116103393B (zh) * 2022-07-18 2025-10-03 江苏大学 一种用于胃癌诊断和/或治疗的circRNA及其应用、检测引物对和诊断试剂盒
CN115595366B (zh) * 2022-07-20 2026-04-28 山东大学齐鲁医院 lncRNA-WEE2-AS1中m6A甲基化水平作为胶质瘤标志物的应用
CN115094143A (zh) * 2022-07-22 2022-09-23 中山大学附属第五医院 长链非编码rna在制备子宫内膜癌预后判断、疗效监测和/或复发监控产品中的应用
CN115927617B (zh) * 2022-08-30 2025-05-23 江西省肿瘤医院(江西省第二人民医院、江西省癌症中心) LncRNA LINC01748在胶质瘤诊断、治疗和提高药物敏感性中的应用
CN116064557B (zh) * 2022-09-15 2024-06-04 华中农业大学 激活猪的ogfod2基因表达的制剂在制备猪抗伪狂犬病毒感染药物中的应用
CN116083574A (zh) * 2022-11-25 2023-05-09 山东第一医科大学第一附属医院(山东省千佛山医院) 长链非编码rna nonhsat017321在结肠癌诊断中的应用
CN116270708B (zh) * 2023-02-06 2024-11-12 华中科技大学同济医学院附属同济医院 LncRNA DCRT的制药用途及其治疗心血管疾病的药物、筛选方法和制备方法
CN116103410B (zh) * 2023-02-09 2024-08-16 新疆畜牧科学院生物技术研究所（新疆畜牧科学院中国-澳大利亚绵羊育种研究中心） 巴音布鲁克羊的育种方法及所用巴音布鲁克羊毛色性状的Indel分子标记
CN116327942B (zh) * 2023-02-13 2024-12-24 广州医科大学附属第五医院 靶向lncRNA CTC-490G23.2的抑制剂在制备抗肿瘤药物中的应用
CN116327795A (zh) * 2023-02-22 2023-06-27 深圳市第二人民医院(深圳市转化医学研究院) Linc01089在制备治疗癌症的药物中的用途
CN116173058B (zh) * 2023-03-08 2025-03-14 天津医科大学第二医院 一种bp-pei@rna纳米药物复合体、制备方法及其在治疗癌症中的应用
CN116287277B (zh) * 2023-04-24 2024-08-06 上海生物制品研究所有限责任公司 胞苷脱氨酶活性的生物标记物及其应用
CN116949162B (zh) * 2023-05-26 2025-10-24 首都医科大学附属北京胸科医院 用于筛查结核病患者的三种lncRNA标志物组合及其应用
CN116769777A (zh) * 2023-06-02 2023-09-19 南通大学 一种促进脊髓损伤后轴突再生的工程化外泌体、制备方法与应用
CN116637123B (zh) * 2023-06-07 2024-02-13 上海市东方医院（同济大学附属东方医院） 敲降或下调C15orf39基因表达的试剂在制备治疗胃癌的药物中的应用
WO2025011736A1 (en) 2023-07-07 2025-01-16 Genxpro Gmbh A METHOD FOR AN IN VITRO DIAGNOSIS, PROGNOSIS, STAGING AND/OR TREATMENT MONITORING OF A NEURODEGENERATIVE DISEASE, NEUROLOGICAL DISEASE OR AMYLOID β-RELATED DISEASE
CN116983414B (zh) * 2023-09-04 2025-09-30 南通大学附属医院 lncRNA MIR181A2HG在制备抑制胃癌淋巴结转移药物中的应用
CN116926189B (zh) * 2023-09-12 2023-12-01 上海益诺思生物技术股份有限公司 外泌体lncRNA在检测药源性心肌损伤中的应用
CN117051102B (zh) * 2023-10-12 2024-01-26 上海爱谱蒂康生物科技有限公司 生物标志物组合在制备预测帕金森病的产品中的应用
CN117305312B (zh) * 2023-10-19 2024-08-20 西南大学 一个家蚕专一取食桑叶的决定基因Zfh3及其应用
CN117653653B (zh) * 2023-10-19 2024-09-06 复旦大学附属肿瘤医院 干预癌特异linc01419的小分子核酸药物及其在肝癌靶向治疗中的应用
CN117701563B (zh) * 2023-11-23 2024-07-02 西南医科大学 一种小分子rna候选药物序列优化及其在糖尿病心肌病治疗中的应用
CN117385024B (zh) * 2023-11-29 2024-04-19 梅州市人民医院(梅州市医学科学院) 一种lncRNA标志物及其在制备诊断、筛查或评估急性冠状动脉综合征的产品中的应用
CN117393044B (zh) * 2023-12-11 2024-02-27 四川大学华西医院 一种用于轻度认知障碍症早期筛查的试剂盒及诊断系统
CN118360406B (zh) * 2024-05-23 2024-10-18 青岛市中心医院 一种肿瘤检测试剂盒及其应用
CN119061137A (zh) * 2024-11-06 2024-12-03 宁波大学附属第一医院 一种用于辅助诊断克罗恩病的eRNA分子标记物及其应用
CN119842882A (zh) * 2024-12-20 2025-04-18 威海市立医院 生物标志物在制备诊断和/或评估t2md卒中后认知障碍的产品中的应用
CN119913153A (zh) * 2025-02-17 2025-05-02 江苏大学 一种LncRNA作为胃癌生物标志物及治疗靶点的应用
CN119799711B (zh) * 2025-03-17 2025-06-13 内蒙古农业大学 一种绒山羊lncRNA、干扰载体及其在调控绒山羊毛囊发育中的应用
CN120648803B (zh) * 2025-06-27 2026-01-06 温州医科大学附属第一医院 用于胃癌诊断的循环snoRNA生物标志物及应用
CN120860224B (zh) * 2025-09-26 2025-12-23 内蒙古医科大学附属医院(内蒙古自治区心血管研究所) LncRNA GSEC在制备治疗口腔鳞癌的药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015031958A1 (en) * 2013-09-06 2015-03-12 Garvan Institute Of Medical Research Regulatory molecules

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6407132B1 (en) 1997-07-25 2002-06-18 James Black Foundation Limited Substituted imidazole derivatives and their use as histamine H3 receptor ligands
AU2005206389A1 (en) 2004-01-27 2005-08-04 Compugen Ltd. Methods of identifying putative gene products by interspecies sequence comparison and biomolecular sequences uncovered thereby
FR2882056B1 (fr) 2005-02-15 2007-06-01 Centre Nat Rech Scient Dipyrromethenes-bore borocarbones insatures
US8802438B2 (en) * 2010-04-16 2014-08-12 Children's Medical Center Corporation Compositions, kits, and methods for making induced pluripotent stem cells using synthetic modified RNAs
US9377472B2 (en) 2012-04-30 2016-06-28 Amoneta Diagnostics Biological complex specific for Alzheimer's disease detection in vitro and use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015031958A1 (en) * 2013-09-06 2015-03-12 Garvan Institute Of Medical Research Regulatory molecules

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DENG, Y. ET AL.: ""Plasma long noncoding RNA 51A as a stable biomarker of Alzheimer’s disease"", INT. J. CLIN. EXP. PATHOL., vol. 10, JPN6023033261, 2017, pages 4694 - 4699, ISSN: 0005304772 *
FENG, L. ET AL.: ""Plasma long non-coding RNA BACE1 as a novel biomarker for diagnosis of Alzheimer disease"", BMC NEUROL., vol. Vol. 18; 4, JPN6023033259, 9 January 2018 (2018-01-09), pages 1 - 8, ISSN: 0005304774 *
GUI, Y. ET AL: ""Altered microRNA profiles in cerebrospinal fluid exosome in Parkinson disease and Alzheimer disease", ONCOTARGET, vol. 6, JPN6023033262, 2015, pages 37043 - 37053, ISSN: 0005304771 *
SOREQ, L. ET AL.: ""Long non-coding RNA and alternative splicing modulations in Parkinson's leukocytes identified by RN", PLOS COMPUT. BIOL., vol. Vol. 10; e1003517, JPN6023033260, 2014, pages 1 - 22, ISSN: 0005304773 *

Also Published As

Publication number Publication date
US20210269881A1 (en) 2021-09-02
EP3847279A1 (en) 2021-07-14
US12344895B2 (en) 2025-07-01
EP3847279C0 (en) 2024-03-06
JP2024073440A (ja) 2024-05-29
WO2020049135A1 (en) 2020-03-12
CN113286895A (zh) 2021-08-20
EP3847279B1 (en) 2024-03-06

Similar Documents

Publication Publication Date Title
US12344895B2 (en) Long non-coding RNAS (LNCRNAS) for the diagnosis and therapeutics of brain disorders, in particular cognitive disorders
EP3679157B1 (en) Non-coding rnas (ncrna) for the diagnosis of cognitive disorders
EP3891295B1 (en) Methods of diagnosing a disease state
Martinez et al. MicroRNAs as diagnostic and therapeutic tools for Alzheimer’s disease: advances and limitations
EP2742155B1 (en) Biomarker for alzheimer's disease and/or mild cognitively impairment
JP6371367B2 (ja) 心的外傷後ストレス障害（ｐｔｓｄ）のための診断用バイオマーカーを検出及び監視するため、並びに同障害の自殺型と非自殺型とを識別するためのプロセス及びキット
CN109055541B (zh) Ad所致mci诊断标志物及其应用
US20230143011A1 (en) METHODS OF DETECTING circRNA
EP3545103B1 (en) Method and biomarkers for in vitro diagnosis of mental disorders
Sakkaki et al. Gene expression patterns of CRYM and SIGLEC10 in Alzheimer's disease: potential early diagnostic indicators
Gu et al. Whole transcriptome sequencing of peripheral blood identifies the Alzheimer's disease-related circRNA-miRNA-lncRNA pathway
US20120208718A1 (en) Schizophrenia treatment response biomarkers
CN116218986A (zh) 一种诊断是否患有阿尔茨海默病的试剂盒及其用途
JP7731540B2 (ja) アミロイドβ蓄積リスクの有無の指標とする方法、一塩基多型（ＳＮＰ）の存在又は非存在を検出する方法、組成物、及びキット
Wu et al. Integrative single-cell and cell-free plasma RNA transcriptomics identifies biomarkers for early non-invasive AD screening
Shireby Regulatory genomic consequences of polygenic risk burden for Alzheimer’s disease
Growdon et al. Biomarkers for Alzheimer’s disease and Parkinson’s disease
Crawford Investigation of analytical bioinformatic approaches to genomic and transcriptomic data
Kerrebijn Elucidating cell types associated with case-control differences in cortical thickness in neuropsychiatric disorders
WO2023085307A1 (ja) 診断マーカー検出方法、及び診断キット
Kouli The neuroinflammatory basis of disease progression and cognitive impairment in Parkinson's disease
WO2020092862A1 (en) Dlgap2 as a therapeutic target for and alzheimer's disease and age-related cognitive decline
Bradley-Smith A population-based study of cognitive decline and peripheral inflammatory gene expression

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220902

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220902

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230816

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231115

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240115

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240416